Jpmorgan Chase & CO Pardes Biosciences, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$1.4 - $1.95 $27,864 - $38,810	-19,903 Reduced 37.14%	33,682 $60,000
Q1 2023 May 18, 2023	BUY	$1.21 - $2.22 $31,825 - $58,390	26,302 Added 96.4%	53,585 $70,000
Q1 2023 May 11, 2023	BUY	$1.21 - $2.22 $8,974 - $16,465	7,417 Added 37.34%	27,283 $36,000
Q4 2022 Feb 13, 2023	BUY	$0.85 - $1.69 $1,065 - $2,117	1,253 Added 6.73%	19,866 $34,000
Q3 2022 Nov 14, 2022	BUY	$2.14 - $3.7 $7,410 - $12,813	3,463 Added 22.86%	18,613 $34,000
Q2 2022 Aug 11, 2022	BUY	$2.84 - $8.57 $43,026 - $129,835	15,150 New	15,150 $47,000

5.23M

Ticker PRDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,320,900
Description
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.